论文部分内容阅读
目的观察醒脑静注射液治疗动脉瘤性蛛网膜下腔出血(a SAH)后认知功能损害的疗效。方法 84例a SAH患者随机分为治疗组和对照组。对照组接受常规治疗,治疗组在常规治疗基础上加用醒脑静注射液(20 m L,每天两次)连续静脉输注2周。在治疗2周后和治疗3月后采用蒙特利尔认知评估量表(MOCA)评定疗效,并观察治疗安全性。结果治疗2周后两组MOCA评分无统计学意义,治疗3月后治疗组MOCA评分显著高于对照组(P=0.001),未发现明显不良反应。结论醒脑静注射液对于改善a SAH患者的认知功能损害疗效肯定,且无严重不良反应。
Objective To observe the effect of xingnaojing injection on cognitive impairment after aneurysmal subarachnoid hemorrhage (a SAH). Methods A total of 84 patients with SAH were randomly divided into treatment group and control group. The control group received routine treatment. The treatment group was given continuous intravenous infusion of Xingnaojing Injection (20 m L twice daily) for 2 weeks on the basis of routine treatment. After 2 weeks of treatment and after 3 months of treatment, the Montreal Cognitive Assessment Scale (MOCA) was used to assess the efficacy and observe the safety of treatment. Results After 2 weeks of treatment, the MOCA scores of the two groups were not statistically significant. After 3 months of treatment, the MOCA score of the treatment group was significantly higher than that of the control group (P = 0.001), and no obvious adverse reactions were found. Conclusion Xingnaojing injection has a definite curative effect on ameliorating cognitive impairment in a SAH patients without serious adverse reactions.